7:50 am Chair’s Opening Remarks

An Overview of Progress Towards Achieving Successful Antigen Specific Therapeutics

8:00 am Antigen-Specific Immunotherapy Approaches for the Treatment of Autoimmune Diseases

  • Emilio Flano Director & Head of Immunology Discovery, Merck & Co

8:30 am Translating Innovative Science to Therapies that Establish Immune Tolerance – One Pharma’s Perspective

  • Arpita Maiti Executive Director & Global Head, Global Head Pfizer

Clinical Readouts & Translation: What can we Learn from the Clinic? Implications for Designing Clinical Trials

9:00 am Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases

  • David Wraith Director of the Institute of Immunology & Immunotherapy , University of Birmingham

9:30 am From Bench to Bedside: Pre-Clinical & Clinical Results of Tolerogenic Therapy of Celiac Disease using Gliadin-Encapsulating PLG Nanoparticles

  • Stephen Miller Co-Founder of Cour Pharmaceuticals; Professor of Microbiology- Immunology, Northwestern University Medical School

10:00 am Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the Antigen-Specific Immune Tolerance field and establish meaningful business relationships to pursue for the rest of the conference.

10:30 am Morning Break & Refreshments

11:00 am From Mechanism to Clinical Trial – Blocking Disease-Specific HLA in Type 1 Diabetes

  • Aaron Michels Associate Professor of Pediatrics Medicine, & Immunology, Barbara Davis Center for Diabetes, University of Colorado; Chief Scientific Officer, IM Therapeutics

11:30 am Mitigation of Anti-Drug Antibodies with ImmTOR Tolerogenic Nanoparticles

12:00 pm Lunch & Networking

Optimizing the Identification of Novel Targets: Evaluation of Antigen & Epitope Discovery

1:00 pm Antigen Discovery for Tolerance Induction (Using Immunoinformatics)

  • Anne De Groot Founder, Chief Executive Officer & Chief Scientific Officer, Epivax

1:30 pm Antigen Discovery as Key Prerequisite for Successful Tolerization & Vaccination Strategies in Autoimmune Diseases, Allergies & Oncology

  • Roland Martin Head - Department of Neuroimmunology & Multiple Sclerosis Research, University Hospital Zurich

Tolerance Delivery Systems & Trial Design Optimization

2:00 pm The Importance of Tolerance Delivery Systems in Antigen-Specific Immune Tolerance

2:30 pm Afternoon Break & Refreshments

3:00 pm A Review of Clinically Tested ASIT Delivery Systems & Implications for Future Design

  • Cory Berkland Cory Berkland Distinguished Professor, School of Pharmacy Pharmaceutical Chemistry, University of Kansas

3:30 pm Bench-to-bedside: Imotope™-based antigen-specific immunotherapy for autoimmune diseases

4:00 pm Panel Discussion title: Optimizing Your Clinical Trial Design: A Case Study From Topas Therapeutics

4:30 pm Novel Approaches to Antigen Delivery & Immune Response Monitoring

  • Colin Dayan Professor of Clinical Diabetes & Metabolism, Cardiff University School of Medicine

5:00 pm Translational & Clinical Development of Novel, Liver Targeted Immune Tolerance Therapies for Celiac Disease & Multiple Sclerosis

5:30 pm Chair’s Closing Remarks

5:40 pm Scientific Poster Session